Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy.
about
Neuro-QOL and the NIH Toolbox: implications for epilepsyThe adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trialsLong-term treatment with responsive brain stimulation in adults with refractory partial seizures.Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial.Safety and tolerability of perampanel: a review of clinical trial data.Screening electroencephalograms are feasible in the emergency department.Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review.Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.Adverse antiepileptic drug effects in new-onset seizures: a case-control study.Clinical utility of eslicarbazepine: current evidence.Safety of pregabalin among hemodialysis patients suffering from uremic pruritus.Baseline psychiatric evaluations are needed to treat seizuresPatient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements.The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment.Tools for assessing quality of life in epilepsy patients.The RNS System: responsive cortical stimulation for the treatment of refractory partial epilepsy.Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?Factors predictive of resilience and vulnerability in new-onset epilepsy.Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs.Factors affecting the quality of life in drug-resistant epilepsy patients.Playing soft, with tough players: Controlling adverse drug effects while tuning antiepileptic drugs, epilepsy & the person.Adverse antiepileptic drug effectsClinic-Based Mobile Health Decision Support to Enhance Adult Epilepsy Self-Management: An Intervention Mapping Approach.Antiepileptic drugs patterns in elderly inpatients in a Brazilian tertiary center, Salvador, Brazil.Adverse effects of carbamazepine monotherapy among patients in Nigeria: a pilot study and implications.Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy.Antiepileptic drugs: Impacts on human serum paraoxonase-1.Patient reported adverse events among epileptic patients taking antiepileptic drugs.Amelioration of Pentylenetetrazole-Induced Seizures by Modulators of Sigma, N-Methyl-D-Aspartate, and Ryanodine Receptors in Mice.Tolerability and safety of perampanel: two randomized dose-escalation studies.
P2860
Q24599341-2F6335B8-3AEE-4EA7-AD08-AE77E622F605Q27026195-8BC0415E-E6F6-464B-A2D4-C4248508B8FDQ30407873-B547EEC6-B1FF-4FCC-98F1-452D710E0095Q30409185-188111E9-587B-4DB7-BBDB-6E2B83520FDAQ30597533-FEC436C8-2400-4DF2-AACE-F81FB92EA188Q33164404-49DDF890-0657-4495-BABC-1C043696A69CQ34007364-D5AA3EBB-E707-42D6-8495-B6CA87D29D8BQ34464379-47B1789D-B3C9-433F-9E86-5D45BFE27C74Q34555287-E5EDE4E8-D450-43C8-99FE-B238058BB8DBQ35087964-3CC467F8-93BB-43C5-A40E-49936DC12240Q36346120-FDA4861E-7343-4DB3-BAEB-25E051328A1DQ36623456-6A0F3C67-015D-47E3-80FA-4D344C3367D3Q36710479-E73E7579-50B6-484F-A6C7-38EDE8667C56Q37841667-E5493AEE-0D7F-4700-B1FA-9C4D287BEF95Q38105151-17AA6471-C2CF-4002-B8A8-4B48C8F6BAE1Q38161535-7F646341-17B6-41EE-9643-F5616E73AA05Q38241684-49C07952-B22C-4B2C-842B-9B56702881D8Q38465542-4EF71403-821A-4F30-AACE-8C8B49BE886EQ39107282-10FD4CDB-D914-4D86-8A8F-3D7EB894188EQ39285287-930350A7-8566-47F0-B590-942D769D70F9Q39962392-A6A9C6D9-5866-4386-AAD2-A71360004BE8Q40871772-0E967F86-FA4A-44CB-BC2F-10BB53264497Q41376742-FE99EDA6-A739-44C1-B7EA-D16897407F2FQ42085468-5C283D99-9E9B-43B1-A60C-2A7047876D2AQ42372556-9FCCB86F-7FE1-498D-B595-24F26181A2C1Q43626330-53A799B0-3BA6-4152-8906-910D95A2626CQ46746109-34A514EA-264A-4AE0-BC09-6F7E5FF06A2DQ48530215-F8A02D0F-3330-4FB4-9177-B0C5CA74296DQ50010969-3D100681-10EA-4D12-AB05-650931CF927AQ51229073-1DEDB5CC-5A8A-4639-8966-E74DF935D2F1Q53682134-1C04D58B-20A3-4D3D-ABE0-EE02477273BDQ54966162-24FE1083-3FB2-48DF-B887-550E6AD177E5Q55054824-2EC44F64-88CF-445D-8A70-EB612949BBE5
P2860
Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@en
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@nl
type
label
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@en
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@nl
prefLabel
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@en
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@nl
P2093
P2860
P1433
P1476
Adverse antiepileptic drug eff ...... iologically relevant taxonomy.
@en
P2093
Frank G Gilliam
Jewell Carter
Piero Perucca
Victoria Vahle
P2860
P304
P356
10.1212/01.WNL.0000345667.45642.61
P407
P577
2009-04-01T00:00:00Z